Basilea Pharmaceutica AG (BPMUF)

Market Cap	709.11M
Revenue (ttm)	297.01M
Net Income (ttm)	91.36M
Shares Out	n/a
EPS (ttm)	6.88
PE Ratio	7.76
Forward PE	10.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15
Average Volume	43
Open	67.75
Previous Close	61.34
Day's Range	67.75 - 67.75
52-Week Range	47.50 - 67.75
Beta	0.71
RSI	68.17
Earnings Date	Aug 19, 2025

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infectiv...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 164
• Stock Exchange: OTCMKTS
• Ticker Symbol: BPMUF

Financial Performance

In 2024, Basilea Pharmaceutica AG's revenue was 208.54 million, an increase of 32.30% compared to the previous year's 157.63 million. Earnings were 77.59 million, an increase of 642.45%.

Financial numbers in CHF